Journal of Clinical Densitometry
Volume 9, Issue 1 , Pages 47-57 , January 2006

Standards for Performing DXA in Individuals With Secondary Causes of Osteoporosis

  • Aliya A. Khan

      Affiliations

    • Divisions of Endocrinology and Geriatrics, McMaster University, Hamilton, Ontario, Canada
    • Corresponding Author InformationAddress correspondence to: Aliya A. Khan, MD, FRCPC, FACP, Associate Clinical Professor of Medicine, Divisions Endocrinology and Geriatrics, McMaster University, 331-209 Sheddon Avenue, Oakville, ON L6J 1X8, Canada.
    • ,
  • David A. Hanley

      Affiliations

    • Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    • ,
  • John P. Bilezikian

      Affiliations

    • College of Physicians and Surgeons, Columbia University, New York, New York
    • ,
  • Neil Binkley

      Affiliations

    • University of Wisconsin, Madison, Wisconsin
    • ,
  • Jacques P. Brown

      Affiliations

    • CHUR Research Centre, Laval University, Quebec City, Quebec, Canada
    • ,
  • Anthony B. Hodsman

      Affiliations

    • University of Western Ontario, London, Ontario, Canada
    • ,
  • Robert G. Josse

      Affiliations

    • University of Toronto, Toronto, Ontario, Canada
    • ,
  • David L. Kendler

      Affiliations

    • University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • E. Michael Lewiecki

      Affiliations

    • New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM
    • ,
  • Paul D. Miller

      Affiliations

    • Colorado Center for Bone Research, Lakewood, CO
    • ,
  • Wojciech P. Olszynski

      Affiliations

    • University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    • ,
  • Steven M. Petak

      Affiliations

    • Texas Institute for Reproductive Medicine, Houston, TX
    • ,
  • Zeba A. Syed

      Affiliations

    • Muscoloskeletal Radiologist, Hanover General Hospital, Hanover, PA
    • ,
  • Diane Theriault

      Affiliations

    • Dartmouth, Nova Scotia, Canada
    • ,
  • Nelson B. Watts

      Affiliations

    • University of Cinncinnati, Cinncinnati, OH

References 

  1. Khan AA, Brown J, Faulkner K, et al. Standards and guidelines for performing central dual x-ray densitometry from the Canadian Panel of International Society for Clinical Densitometry. J Clinic Densitom. 2002;5:435–445
  2. Khan AA, Bachrach L, Brown JP, et al. Standards and guidelines for performing central dual x-ray densitometry in premenopausal women, men, and children from the Canadian Panel of the International Society of Clinical Densitometry. J Clin Densitom. 2004;7:51–63
  3. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15(6):993–1000
  4. Gudbjornsson B, Juliusson UI, Gudjonsson FV. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis. 2002;61(1):32–36
  5. Mudano A, Allison J, Hill J, Rothermel T, Saag K. Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort. J Rheumatol. 2001;28(6):1298–1305
  6. Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ. 1996;313(7053):344–346
  7. Van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM. 2000;93(2):105–111
  8. Donnan PT, Libby G, Boyter AC, Thompson P. The population risk of fractures attributable to oral corticosteroids. Pharmacoepidemiol Drug Saf. 2005;14(3):177–186
  9. LoCascio V, Bonucci E, Imbimbo B, Ballanti P, Tartarotti D, Galvanini G, et al. Bone loss after glucocorticoid therapy. Calcif Tissue Int. 1984;36(4):435–438
  10. Adachi JD, Bensen WG, Bianchi F, RJ, et al. 1996 Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year follow-up. J Rheumatol 23(6):995–1000.
  11. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med. 1983;309(5):265–268
  12. Michel BA, Bloch DA, Fries JF. Predictors of fractures in early rheumatoid arthritis. J Rheumatol. 1991;18(6):804–808
  13. Dykman TR, Gluck OS, Murphy WA, Hahn TJ, Hahn BH. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum. 1985;28(4):361–368
  14. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39(12):1383–1389
  15. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48(11):3224–3229
  16. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19(6):893–899
  17. Van Staa TP, Cooper C, Leufkens HG, Bishop N. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res. 2003;18(5):913–918
  18. Richy F, Bousquet J, Ehrlich GE, et al. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int. 2003;14(3):179–190
  19. Hubbard RB, Smith CJ, Smeeth L, Harrison TW, Tattersfield AE. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med. 2002;166(12 Pt 1):1563–1566
  20. Suissa S, Ernst P. Inhaled corticosteroids and fracture risk in COPD. Am J Respir Crit Care Med. 2004;170(1):94–95
  21. Lee TA, Weiss KB. Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169(7):855–859
  22. Van Staa TP, Bishop N, Leufkens HG, Cooper C. Are inhaled corticosteroids associated with an increased risk of fracture in children?. Osteoporos Int. 2004;15(10):785–791
  23. Schwid SR, Goodman AD, Puzas JE, McDermott MP, Mattson DH. Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol. 1996;53(8):753–757
  24. Haugeberg G, Griffiths B, Sokoll KB, Emery P. Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study. Ann Rheum Dis. 2004;63(8):940–944
  25. Choy EH, Kingsley GH, Khoshaba B, Pipitone N, Scott DL. A 2 year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann Rheum Dis. 2005;64(9):1288–1293
  26. Chantler IW, Davie MW, Evans SF, Rees JS. Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service. Ann Rheum Dis. 2003;62(4):350–352
  27. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997;337(6):382–387
  28. Saag KG, Emkey R, Schnitzer TJ, et al. Glucocorticoid-Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998;339(5):292–299
  29. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000;67(4):277–285
  30. Hanley DA, Davison KS. Vitamin D insufficiency in North America. J Nutr. 2005;135:332–337
  31. Rosen CJ, Black DM, Greenspan SL. Vignettes in osteoporosis: a road map to successful therapeutics. J Bone Miner Res. 2004;19:3–10
  32. Segal E, Baruch Y, Kramsky R, Raz B, Tamir A, Ish-Shalom S. Predominant factors associated with bone loss in liver transplant patients after prolonged post-transplantation period. Clin Transplant. 2003;17:13–19
  33. Vage V, Gjesdal CG, Eide GE, Halse JI, Viste A. Bone mineral density in females after jejunoileal bypass: a 25-year follow-up study. Obes Surg. 2004;14:305–312
  34. Haderslev KV, Jeppesen PB, Sorensen HA, Mortensen PB, Staun M. Vitamin D status and measurements of markers of bone metabolism in patients with small intestinal resection. Gut. 2003;52:653–658
  35. Jahnsen J, Falch JA, Mowinckel P, Aadland E. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol. 2002;37:192–199
  36. Siffledeen JS, Siminoski K, Steinhart H, Greenberg G, Fedorak RN. The frequency of vitamin D deficiency in adults with Crohn's disease. Can J Gastroenterol. 2003;17:473–478
  37. Ghose R. Post-gastrectomy bone disease undiagnosed for forty years. N Z Med J. 1999;112:290–292
  38. Donovan DS, Papadopoulos A, Staron RB, et al. Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease. Am J Respir Crit Care Med. 1998;157:1892–1899
  39. Valdimarsson T, Lofman O, Toss G, Strom M. Reversal of osteopenia with diet in adult coeliac disease. Gut. 1996;38:322–327
  40. Nieves J, Cosman F, Herbert J, Shen V, Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology. 1994;44:1687–1692
  41. Gough H, Goggin T, Bissesar A, Baker M, Crowley M, Callaghan N. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy. Q J Med. 1986;59(230):569–577
  42. Webb AR, Pilbeam C, Hanafin N, Holick MF. An evaluation of the relative contributions of exposure to sunlight and of diet to the circulating concentrations of 25-hydroxyvitamin D in an elderly nursing home population in Boston. Am J Clin Nutr. 1990;51:1075–1081
  43. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab. 1988;67:373–378
  44. Matsuoka LY, Wortsman J, Hollis BW. Use of topical sunscreen for the evaluation of regional synthesis of vitamin D3. J Am Acad Dermatol. 1990;22:772–775
  45. Holick MF, Matsuoka LY, Wortsman J. Regular use of sunscreen on vitamin D levels. Arch Dermatol. 1995;131:1337–1339
  46. Food and Nutrition Board, Institute of Medicine . Dietary reference intakes for calcium, magnesium, phosphorus, vitamin D, and fluoride. Washington, DC: National Academy Press; 1997;
  47. Rucker D, Allan JA, Fick GH, Hanley DA. Vitamin D insufficiency in a population of healthy western Canadians. CMAJ. 2002;166:1517–1524
  48. Heaney RP. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr. 2004;80(Suppl 6):1706S–1709S
  49. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7:439–443
  50. Riggs BL, O'Fallon WM, Muhs J, O'Connor MK, Kumar R, Melton LJ. Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women. J Bone Miner Res. 1998;13:168–174
  51. Marcus R, Madvig P, Young G. Age-related changes in parathyroid hormone and parathyroid hormone action in normal humans. J Clin Endocrinol Metab. 1984;58:223–230
  52. Vieth R, Ladak Y, Walfish PG. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab. 2003;88:185–191
  53. Binkley N, Krueger D, Cowgill CS, et al. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab. 2004;89:3152–3157
  54. Hollis BW. Editorial: the determination of circulating 25-hydroxyvitamin D: no easy task. J Clin Endocrinol Metab. 2004;89:3149–3151
  55. Koster JC, Hackeng WH, Mulder H. Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women. Eur J Clin Pharmacol. 1996;51:145–147
  56. Grados F, Brazier M, Kamel S, et al. Effects on bone mineral density of calcium and vitamin D supplementation in elderly women with vitamin D deficiency. Joint Bone Spine. 2003;70:203–208
  57. Arekat MR, And G, Lemke S, Moses AM. Dramatic improvement of BMD following vitamin D therapy in a bone marrow transplant recipient. J Clin Densitom. 2002;5:267–271
  58. Adams JS, Kantorovich V, Wu C, Javanbakht M, Hollis BW. Resolution of vitamin D insufficiency in osteopenic patients results in rapid recovery of bone mineral density. J Clin Endocrinol Metab. 1999;84:2729–2730
  59. Stedman's Medical Dictionary. 26th ed.. Baltimore: Williams & Wilkins; 1995;836
  60. Petak SM, Nankin HR, Spark RF, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients—2002 update. Endocr Pract. 2002;8:440–456
  61. Seftel A. Male hypogonadism. Part II: etiology, pathophysiology, and diagnosis. Int J Impot Res Aug 11. 2005;11:[Epub ahead of print]
  62. Orwoll ES, Ettinger M, Weiss S, Miller P, et al. Alendronate treatment of Osteoporosis in Men. J Bone Miner Res. 1999;14:S184
  63. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18:9–17
  64. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84:1966–1972
  65. Scholes D, Lacroix AZ, Ott SM, et al. Bone mineral density in women using dept medroxyprogesterone acetate for contraception. Arch Pediatr Adolesc Med. 2005;159(2):139–144
  66. Klibanski A, Biller BM, Schoenfeld DA, et al. The effects of estrogen administration of trabecular bone loss in young women with anorexia nervosa. J Clin Endocrinol Metab. 1995;80:898–904
  67. Grimes DA, Lobo RA. Perspectives on the Women's Health Initiative trial of hormone replacement therapy. Obstet Gynecol. 2002;100(6):1344–1353
  68. U.S. Preventive Services Task Force of the U.S. Dept of Health's Agency for Healthcare Research and Quality. September 2002 guidelines. Available at: http://www.ahrg.gov/clinic/uspstf/uspsoste.htm. Accessed December 20, 2005.
  69. National Osteoporosis Foundation. NOF guidelines for bone density testing. Available at: http://www.nof.org/osteoporosis/bonemass.htm. Accessed December 20, 2005.
  70. Hodgson SF, Watts NB, Bilezikian JP, et al. for the AACE Osteoporosis Task Force. 2003 American Association of Clinical Endocrinologists medical guidelines for clinical practice and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. [published correction appears in Endocr Pract 10–90] Endocr Pract. 2004;9(6):544–564
  71. Lewiecki EM, Watts NB, McClung MR, et al. International Society for Clinical Densitometry. Official positions of the international society for clinical densitometry. J Clin Endocrinol Metab. 2004;89:3651–3655
  72. Khan AA, Syed ZA. Skeletal effects of primary hyperparathyroidism. Endocr Pract. 2000;6:385–388
  73. Silverberg SJ, Shane E, Jacobs TP, et al. 1999 A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery [erratum in N Engl J Med 2000;342:144] N Engl J Med 241:1249–1255.
  74. Khosla S, Melton LJ, Wermers RA, et al. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res. 1999;14:1700–1707
  75. Dempster DW, Caldwell NJ, Goldstein SA, et al. Three-dimensional assessment of trabecular architecture in mild primary hyperparathyroidism. [abstract] J Bone Miner Res. 2002;17(Suppl):S166
  76. Bilezikian JP, Potts JT, Fuleihan G-H, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Miner Res. 2002;17(Suppl 2):N2–N11
  77. Miller PD, Bilezikian JP. Bone densitometry in asymptomatic primary hyperparathyroidism. J Bone Miner Res. 2002;17(Suppl 2):N98–N102
  78. Khan AA, Hanley DA, O'Brien CJ, et al. Position paper: asymptomatic primary hyperparathyroidism - standards and guidelines for diagnosis and management in Canada. Endocr Pract. 2003;9:400–405
  79. Nakoaka D, Sugimoto T, Kobayashi T, et al. Prediction of bone mass change after parathyroidectomy in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2000;85(5):1901–1907
  80. Grey AB, Stapleton JP, Evans MC, et al. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism: a randomized controlled trial. Ann Intern Med. 1996;125:360–368
  81. Orr-Walker BJ, Evans MC, Clearwater JM, et al. Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women. Arch Intern Med. 2000;160(14):2161–2166
  82. Chow CC, Chan WB, Li JK, et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:581–587
  83. Rubin MR, Lee KH, McMahon DJ, et al. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:1174–1178
  84. Khan AA, Bilezikian JP, Kung AW, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;90:3319–3325
  85. Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Metab. 1994;9:1137–1141
  86. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Brit Med J. 1996;312:1254–1259
  87. Kanis JA, Johnell O, Oden O, Dawson A, De Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. 2001;12:989–995
  88. Massry SG, Coburn JW. K/DOQI Clinical Guidelines for bone metabolism and disease in chronic renal disease. Am J Kidney Dis. 2003;42(Suppl 3):S1–S201
  89. Malluche H, Faugere M-C. Renal bone disease: an unmet challenge for the nephrologist. Kidney Int. 1990;38:193–211
  90. Parfitt AM. Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertension. 2003;12:387–403
  91. Sprague SM, Josephson MA. Bone disease after transplantation. Seminars in Nephrology. 2004;24:82–90
  92. Cohen A, Sambrook P, Shane E. Management of bone loss after organ transplantation. J Bone Min Res. 2004;19:1919–1932
  93. Cohen A, Ebeling P, Sprague S, Shane E. Transplantation osteoporosis. In:  Favus MJ editors. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Washington, DC: American Society for Bone and Mineral Research; 2003;p. 370–379
  94. Hodsman AB. Fragility fractures in dialysis and transplant patients. Is it osteoporosis, and how should it be treated?. Perit Dial Int. 2001;21(Suppl 3):S247–S255
  95. Piraino B, Chen T, Cooperstein L, Segre G, Puschett J. Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol. 1988;30:57–62
  96. Erlichman M, Holohan TV. Bone densitometry: patients with end-stage renal disease. Health Technol Assess. 1996;8:1–27
  97. Matuszkiewicz-Rowinska J, Skorzewska K, Radowicki S, et al. The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Nephrol Dial Transplant. 1999;14:1238–1243
  98. Taal MW, Masud T, Green D, Cassidy M. Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant. 1999;14:1922–1928
  99. Yamaguchi T, Kanno E, Tsubota J, Shiomi T, Nakai M, Hattori S. Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures. Bone. 1996;19:549–555
  100. Lindberg JS, Moe SM. Osteoporosis in end-stage renal disease. Seminars in Nephrology. 1999;19:115–122
  101. Cunningham J, Sprague SM, Cannata-Andia J, et al. Osteoporosis in chronic kidney disease. Am J Kidney Dis. 2004;43:566–571
  102. Fontaine MA, Albert A, Dubois B, Saint-Remy A, Rorive G. Fracture and bone mineral density in hemodialysis patients. Clinical Nephrology. 2000;54:218–226
  103. Gabay Ruedin, Slosman D, Bonjour J-P, Leski Rizzoli R. Bone mineral density in patients with end-stage renal failure. Am J Nephrol. 1993;13:115–123
  104. Weisinger JR, Gonzalez L, Alvarez H, et al. Role of persistent amenorrhea in bone mineral metabolism of young hemodialyzed women. Kidney Int. 2000;58:331–335
  105. Julian BA, Laskow DA, Dubovsky J, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med. 1991;325:544–550
  106. ter Meulen CG, van Riemsdijk I, Hene RJ, et al. No important influence of limited steroid exposure on bone mass during the first year after renal transplant: a prospective, randomized, multicenter study. Transplantation. 2004;78:101–106
  107. Grotz WH, Mundinger FA, Gugel B, Exner VM, Kirste G, Schollmeyer PJ. Bone fracture and osteodensitometry with dual energy x-ray absorptiometry in kidney transplant recipients. Transplantation. 1994;58:912–915
  108. Van Staa TP, Leufkens HG, Abenhaim L. Use of oral corticosteroids and risk factors. J Bone Miner Res. 2000;15:993–1000
  109. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002;167:S1–S34
  110. Guyatt GH, Cranney A, Griffith L, et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fracture risk. Endocrinol Metab Clin North Am. 2002;31:659–679
  111. Hernandez E, Valera R, Alonzo E, et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int. 2003;63:2269–2274
  112. Fan SL-S, Almond MK, Ball E, Evans K, Cunningham J. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int. 2000;7:684–690
  113. Fan SL, Kumar S, Cunningham J. Long-term effects on bone mineral density of pamidronate given at the time of transplantation. Kidney Int. 2003;63:2275–2279
  114. Coco M, Glicklich D, Faugere MC, et al. Prevention of bone loss in renal transplant recepients: A prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol. 2003;14:2669–2676
  115. Grotz W, Nagel C, Poeschel D, et al. Effect of ibandronate on bone loss and renal function after kidney tansplantation. J Am Soc Nephrol. 2001;12:1530–1537
  116. Haas M, Leko-Mohr Z, Roschger P, et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int. 2003;63:1130–1136
  117. Koc M, Tuglular S, Arikan H, Ozener C, Akolglu E. Alendronate increases bone mineral density in long-term renal transplant recipients. Transplant Proc. 2002;34:2111–2113
  118. Giannini S, Dangel A, Carraro G, et al. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res. 2001;16:2111–2117
  119. Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplant. 2003;76:1498–1502
  120. Schwarz C, Mitterbauer C, Heinze G, Woloszczuk W, Hass M, Oberbauer R. Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation. Kidney Int. 2004;65:304–309

 This document was created by the ISCD Canadian Regional Panel. The ISCD has approved this document as being relevant to local or regional needs and does not necessarily represent official ISCD positions or ISCD positions as they relate to this specific jurisdiction.

PII: S1094-6950(06)00020-5

doi: 10.1016/j.jocd.2006.01.001

Journal of Clinical Densitometry
Volume 9, Issue 1 , Pages 47-57 , January 2006

Article Tools